The groundbreaking success of Viagra undeniably reshaped the drug landscape, but placing funds in companies strongly reliant on unbranded versions presents a complex picture. Although early profits were impressive, the cessation of patents and the rise of less expensive alternatives have eroded the customer base. Thus, a thorough evaluation of curr